Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04952753 | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC(daNIS-3) | terminated | Phase 2 | 204 | Novartis PharmaceuticalsINDUSTRY | 17 | Mar 26, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 |
| Mar 21, 2025 |
| clinicaltrials |
| NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 3 | 652 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 21, 2025 | clinicaltrials |
| NCT03280030 | A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2025 | clinicaltrials |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | completed | Phase 3 | 369 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer(MONALEESA-2) | completed | Phase 3 | 668 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT02842749 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | completed | Phase 4 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT01828099 | LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | completed | Phase 3 | 376 | Novartis PharmaceuticalsINDUSTRY | 29 | Jan 16, 2025 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT06692803 | Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy(ABL-2022-03) | completed | — | 2,043 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04507919 | Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT04544202 | Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT03839823 | Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer(RIGHT Choice) | completed | Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 13 | Oct 9, 2024 | clinicaltrials |
| NCT04139317 | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | terminated | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 16 | Oct 9, 2024 | clinicaltrials |
| NCT04323436 | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | terminated | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | Oct 9, 2024 | clinicaltrials |
| NCT04899349 | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant(EPIK-B4) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2024 | clinicaltrials |
| NCT06619704 | Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy | completed | — | 194 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 4, 2024 | clinicaltrials |
| NCT01737827 | Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. | terminated | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 24, 2024 | clinicaltrials |
| NCT01863745 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | completed | Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2024 | clinicaltrials |
| NCT04946305 | A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea | completed | — | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05219266 | Managed Access Programs for PKC412, Midostaurin | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 28, 2024 | clinicaltrials |
| NCT03301896 | Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 | 45 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 20, 2024 | clinicaltrials |
| NCT03610724 | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients(BIANCA) | completed | Phase 2 | 34 | Novartis PharmaceuticalsINDUSTRY | 14 | Jun 20, 2024 | clinicaltrials |
| NCT03968419 | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.(CANOPY-N) | terminated | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 20, 2024 | clinicaltrials |
| NCT04862143 | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant(TELEPIK) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT03484923 | Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma(PLATforM) | completed | Phase 2 | 196 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 18, 2024 | clinicaltrials |
| NCT05853445 | A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera(PAVE) | completed | — | 467 | Novartis PharmaceuticalsINDUSTRY | 1 | May 6, 2024 | clinicaltrials |
| NCT06392763 | Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data | completed | — | 602 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT02445248 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients(JULIET) | completed | Phase 2 | 115 | Novartis PharmaceuticalsINDUSTRY | 10 | Apr 18, 2024 | clinicaltrials |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06337617 | A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma | completed | — | 90 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT05421091 | Special Drug Use-results Surveillance of Scemblix Tablets | completed | — | 550 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02414139 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | completed | Phase 2 | 373 | Novartis PharmaceuticalsINDUSTRY | 20 | Mar 20, 2024 | clinicaltrials |
| NCT02081378 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | completed | Phase 1 | 326 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 18, 2024 | clinicaltrials |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(MONALEESA-7) | completed | Phase 3 | 672 | Novartis PharmaceuticalsINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT04816214 | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy(GEOMETRY-E) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 5, 2024 | clinicaltrials |
| NCT06271369 | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. | completed | — | 613 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT06251934 | Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma | completed | — | 785 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT03312738 | A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor(BOLERO-5) | completed | Phase 2 | 159 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials